

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACRUX DDS PTY LTD. & ACRUX LIMITED
Petitioners,

v.

KAKEN PHARMACEUTICAL CO., LTD. and
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Patent Owner and Licensee.

Case: IPR2017-00190
U.S. Patent No. 7,214,506

DECLARATION OF BONI E. ELEWSKI, M.D.

TABLE OF CONTENTS

	Page(s)
I. Introduction.....	1
A. Professional Qualifications and Expertise	1
B. Compensation.....	4
C. Review and Use of Documents and Other Materials.....	5
II. Summary of Opinions.....	6
III. Applied Legal Standards	7
A. Claim Construction.....	8
B. Person of Ordinary Skill.....	9
C. Prior Art and Priority.....	10
D. Obviousness.....	11
IV. Technical Background.....	13
A. Onychomycosis	13
B. The Morphology of the Nail.....	16
C. Unique Challenges of Treating Fungal Infections of the Nail.....	18
D. Uncertainty in the Art Regarding the Factors Contributing to the Effectiveness of a Topical Treatment Hindered Development	21
E. Many Antifungal Agents were Available Prior to the '506 Patent but Lacked Proven Efficacy in Treating Onychomycosis Topically.....	24
V. The Discovery of Efinaconazole was a Breakthrough for the Field	30
A. The Claimed Invention and the '506 Specification	30

B.	Efinaconazole displays superior efficacy.....	34
C.	Relevant Field and the Person of Ordinary Skill in the Art.....	35
D.	Claim Construction.....	37
VI.	Priority Date of the '506 Patent.....	39
VII.	The Claims of the '506 Patent are Not Obvious	40
A.	The Primary References Only Relate to the Use of Efinaconazole in Skin.....	41
1.	The Kaken Abstracts Test Efinaconazole <i>In Vitro</i> and In a Guinea Pig Model of Skin Infection	41
2.	Ogura is Not Available as Prior Art and Regardless It Does not Add Anything to What the Kaken Abstracts Disclose	46
B.	The Secondary Art Cited by Petitioner Only Discussed the Nail Penetrance of Unrelated Compounds.....	49
1.	JP '639 Only Evaluates the Structurally Unrelated Compound Amorolfine	49
2.	Amorolfine's Underwhelming Efficacy Is Further Evidende of Unpredictability	50
3.	The '367 Patent and Hay Only Evaluate Another Structurally Unrelated Compound, Tioconazole	52
4.	The '367 Patent Fails to Offer Any Data Establishing Efficacy for Tioconazole, Let Alone Any Other Compounds	53
5.	Hay Likewise Fails to Offer any Data Establishing Efficacy for Tioconazole Because of Poor Study Design	53
C.	No Motivation to Apply the Claimed Triazole Compounds to Nail with a Reasonable Expectation of Successfully Treating Onychomycosis	55

D. Neither Claim 1 Nor Claim 2 of the '506 Patent is Obvious58

VIII. Objective Indicia of Nonobviousness.....58

IX. CONCLUSION.....63

I. Introduction

1. I Dr. Boni E. Elewski, M.D., have been retained by Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., to provide the following declaration on behalf of Kaken Pharmaceutical Co., Ltd. and Valeant Pharmaceuticals International, Inc. (collectively, “Patent Owner”) for *inter partes* review Case No. IPR2017-00190 regarding U.S. Patent No. 7,214,506 (“the ’506 patent”). I understand that this IPR resulted from a petitioned filed by Acrux DDS PTY LTD. and Acrux Limited (collectively, “Petitioner”).

A. Professional Qualifications and Expertise

2. I am currently the Chair of the Department of Dermatology and the James E. Elder M.D. Endowed Professor for Graduate Medical Education in Dermatology at the University of Alabama at Birmingham. I have worked in the Department of Dermatology at the University of Alabama since December 1999. Prior to that, from 1982 through December 1999, I was a faculty member at Case Western Reserve University School of Medicine and my responsibilities there included teaching dermatology residents.

3. I hold an M.D. from The Ohio State University College of Medicine (1978) and completed a residency in dermatology at the University of North Carolina Memorial Hospital from 1979-1982.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.